# Retatrutide: Frequently Asked Questions

> Retatrutide FAQ: 25 common questions answered — mechanism, side effects, FDA approval status, dosage, half-life, availability, and comparison with other agonists. Cited from clinical trial data.

These are the most common questions about Retatrutide answered directly from the clinical trial record. Every quantitative claim is cited.

## What is Retatrutide?

Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly that simultaneously activates three gut hormone receptors: GIP, GLP-1, and glucagon receptors [6]. Phase 2 data: 24.2% mean weight reduction at 48 weeks. Phase 3 TRIUMPH-1: 28.3% at 80 weeks at the highest dose [1, 9].

## What does Retatrutide do to your body?

Activates GLP-1 receptors (appetite suppression, slowed gastric emptying), GIP receptors (insulin potentiation, adipocyte signaling), and glucagon receptors (hepatic fat oxidation, brown adipose tissue thermogenesis) [6]. Combined result: greater appetite suppression, greater energy expenditure, and larger weight reduction than dual or mono agonists in separate trial programs.

## How does Retatrutide work?

Binds and activates three G-protein-coupled receptors simultaneously via a single 39-amino acid peptide backbone [6]. Cryo-EM structural studies resolved the atomic mechanism: conserved salt-bridge contacts anchor the peptide across all three receptors; receptor-specific ECL1 loop conformations allow distinct engagement per receptor [6]. Shared cAMP second-messenger pathway mediates appetite suppression, insulin potentiation, and thermogenesis.

## What is Retatrutide used for?

Phase 2 and Phase 3 trials: obesity (BMI ≥30 or ≥27 with comorbidities) and type 2 diabetes [4, 9]. Secondary investigations: MASLD, knee osteoarthritis with obesity [10], cardiovascular outcomes [21], renal effects [18], and preclinical oncology [8]. No approved indication as of mid-2026.

## Is Retatrutide FDA approved?

Not approved as of mid-2026. Phase 3 TRIUMPH-1 results reported May 2026. NDA submission anticipated Q4 2026 [21]. Standard 10-month FDA review: approval projected late 2027 to Q1 2028.

## When will Retatrutide be available?

NDA submission anticipated Q4 2026; standard 10-month review projects approval late 2027 to Q1 2028 [21]. Priority review (6 months) would pull that forward if granted. These are planning projections.

## What are the side effects of Retatrutide?

Most common (Phase 2, 12 mg): nausea ~60%, diarrhea 15–33%, vomiting 21–26%, constipation 11–16%, injection-site reactions ~8% [3]. Phase 3 TRIUMPH-1 at 12 mg: nausea 42.4%, diarrhea 32.0%, constipation 26.1%, vomiting 25.3% [23]. GI events predominantly mild to moderate, most prominent during dose-escalation.

## What are the risks of taking Retatrutide?

Beyond GI events: heart rate increase up to 6.7 beats/min (GCGR-mediated, peaking at 24 weeks) [16]; single atrial fibrillation event in Phase 2 T2D cohort [16]; theoretical class-effect pancreatitis and thyroid C-cell risks — neither observed in Phase 3 data [23]. Cardiovascular outcomes: under study in TRIUMPH-OUTCOMES.

## What happens when you stop taking Retatrutide?

No Retatrutide-specific discontinuation trial published. Class-effect: semaglutide STEP 4 showed 6.9% regain; tirzepatide SURMOUNT-4 showed 14.0% regain after switching to placebo [19]. Most weight recovered within 12 months. Mechanism: recovery of orexigenic signaling.

## Does Retatrutide target belly fat?

Phase 2 data: 86.0% relative hepatic fat reduction at 48 weeks at 12 mg; 93% reached normal liver fat (<5%) [15]. MASLD trial: 82.4% liver fat reduction at 24 weeks [7]. GCGR drives hepatic fat oxidation directly [12].

## What to expect when taking Retatrutide

Phase 2/3 trial participants: appetite suppression within 4 weeks, significant weight loss detectable by week 8, weight accrual over 48–80 weeks [22, 9]. Phase 3 TRIUMPH-1 at 12 mg: 28.3% at 80 weeks; 45.3% achieving ≥30% loss [9]. GI adverse events most prominent during dose-escalation [3].

## How does Retatrutide differ from semaglutide and tirzepatide?

Semaglutide is a GLP-1-only receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist that adds glucagon receptor activation on top of GIP and GLP-1R co-agonism [6]. The additional glucagon receptor engagement drives brown adipose tissue thermogenesis — a mechanism absent in the other two compounds. Indirect comparison of separate Phase 3 trials: Retatrutide at 12 mg produced 28.3% mean weight reduction at 80 weeks, exceeding published semaglutide 2.4 mg Phase 3 results (~14.9%) and tirzepatide peak data (~22.5%) [17]. No controlled head-to-head trial has been published.

## Is Retatrutide a natural hormone?

No. Synthetic engineered peptide with a C20 fatty diacid conjugation that does not occur naturally [14]. C20 conjugation enables ~6-day half-life [5].

## Do you need a prescription for Retatrutide?

Not yet applicable as of mid-2026. Accessible only through registered clinical trials [21]. Prescription pathway opens only after FDA approval.

## Is Retatrutide a GLP-3?

"GLP-3" is not an official pharmacological classification [14]. Accurate description: triple GIP/GLP-1/glucagon receptor agonist or GGG triple agonist.

## Is Retatrutide better than tirzepatide?

No published head-to-head trial as of mid-2026. Indirect: TRIUMPH-1 at 12 mg: 28.3% at 80 weeks; tirzepatide Phase 3 peak: ~22.5% [13]. Mechanistic attribution: GCGR-mediated brown adipose tissue thermogenesis [12]. NCT06662383 registered but not yet reported.

## What is the half-life of Retatrutide?

Approximately 6 days (Urva et al., Lancet 2022) [5]. Dose-proportional across 0.5–12 mg. C20 fatty diacid conjugation enables albumin binding.

## How long does Retatrutide take to work?

Meaningful appetite suppression within 4 weeks; significant weight reduction by week 8; accrual continued without plateau at 48 weeks (Phase 2) [22] and through 80 weeks (Phase 3 TRIUMPH-1) [9].

## What is Retatrutide made of?

39-amino acid acylated peptide with a C20 fatty diacid moiety via lysine-17 linker [6, 14]. ~8.9× more potent at GIPR than endogenous GIP; less potent than natural ligands at GLP-1R and GCGR [14].

## What company makes Retatrutide?

Eli Lilly and Company (Indianapolis, Indiana, US), internal designation LY3437943 [21].

## How does Retatrutide compare to semaglutide?

Phase 3: Retatrutide 28.3% at 80 weeks (TRIUMPH-1) [9]; semaglutide 2.4 mg ~14.9% at 68 weeks (STEP 1) [17]. In pooled Phase 2 data, 64% of 12 mg participants achieved ≥20% loss [17]. No controlled head-to-head trial published.

## How is Retatrutide administered?

Subcutaneous injection, once weekly [5, 1, 9]. Dose escalation from lower starting doses every 4 weeks to maintenance dose (4, 9, or 12 mg in TRIUMPH-1) [9].

## What is Retatrutide's approval status in the US?

Investigational as of mid-2026. NDA submission anticipated Q4 2026; approval projected late 2027 to Q1 2028 under standard 10-month review [21].

## Do you gain weight back after stopping Retatrutide?

Class-effect data: most weight regained within 12 months [19]. Semaglutide STEP 4 and tirzepatide SURMOUNT-4 both documented substantial regain [19]. No Retatrutide-specific discontinuation trial published.

## What receptors does Retatrutide target?

GIPR, GLP-1R, and GCGR — all three G-protein-coupled receptors simultaneously confirmed by cryo-EM [6]. ~8.9× more potent at GIPR than endogenous GIP [14].

## References

[1] Jastreboff AM, et al. N Engl J Med. 2023;389:514-526. DOI: 10.1056/NEJMoa2301972
[3] Same source, adverse events.
[4] Rosenstock J, et al. Lancet. 2023. DOI: 10.1016/S0140-6736(23)01053-X
[5] Urva S, et al. Lancet. 2022;400:1869-1881. DOI: 10.1016/S0140-6736(22)02033-5
[6] Li W, et al. Cell Discovery. 2024. DOI: 10.1038/s41421-024-00700-0
[7] Sanyal AJ, et al. Nat Med. 2024. DOI: 10.1038/s41591-024-03018-2
[8] Marathe SJ, et al. NPJ Metab Health Dis. 2025. DOI: 10.1038/s44324-025-00054-5
[9] Eli Lilly. TRIUMPH-1 press release. 2026.
[10] Eli Lilly. TRIUMPH-4 press release. 2025.
[11] Abouelmagd AA, et al. Proc (Bayl Univ Med Cent). 2025.
[12] Goldney J, et al. Curr Cardiovasc Risk Rep. 2025.
[13] Same source, indirect comparison.
[14] Katsi V, et al. Biomolecules. 2025.
[15] Same source, hepatic fat outcomes.
[16] Doggrell SA. Expert Opin Investig Drugs. 2023.
[17] Goldney J, et al. Same, semaglutide comparison.
[18] Heerspink HJL, et al. Kidney Int Rep. 2025.
[19] Quarenghi M, et al. J Clin Med. 2025.
[21] Eli Lilly. ClinicalTrials.gov NCT05882045. 2023.
[22] Jastreboff AM, et al. Same as [1], onset data.
[23] The Pharmaceutical Journal. 2026.

---

Plain-language summaries of the Phase 2 and Phase 3 Retatrutide trial record — independent, cited, and not a clinical service.